Drug Trial Radar · NCT05602194
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Aug 24, 2023
Primary completion
Sep 30, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- First posted
- Nov 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Conditions
- B Acute Lymphoblastic Leukemia
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
- Lymphoblastic Lymphoma
- Mixed Phenotype Acute Leukemia
- T Acute Lymphoblastic Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Calaspargase PegolDrug
Given standard of care calaspargase pegol
LevocarnitineDietary supplement
Given PO or IV
PegaspargaseDrug
Given standard of care pegaspargase
Quality-of-Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of conjugated hyperbilirubinemia > 3 mg/dL during induction therapyTime frame: During induction therapy (up-to 35-days after initiating induction chemotherapy)
Locations
228 sites in 2 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Kingman Regional Medical Center
Kingman, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
PCR Oncology
Arroyo Grande, California
Kaiser Permanente-Bellflower
Bellflower, California
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente-Fontana
Fontana, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente-San Diego Mission
San Diego, California
Kaiser Permanente-San Diego Zion
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Alfred I duPont Hospital for Children
Wilmington, Delaware
Children's National Medical Center
Washington D.C., District of Columbia
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
Nicklaus Children's Hospital
Miami, Florida
Miami Cancer Institute
Miami, Florida
AdventHealth Orlando
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Nemours Children's Clinic - Pensacola
Pensacola, Florida
Sacred Heart Hospital
Pensacola, Florida
Johns Hopkins All Children's Hospital
St. Petersburg, Florida
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.